Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863450/0/en/Foghorn-Therapeutics-Strengthens-Financial-Leadership-with-Appointment-of-Kristian-Humer-as-Chief-Financial-Officer.html

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.